Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N-dimethylglycine (DMG) is a naturally occurring amino acid derivative found in the cells of all plants and animals and can be obtained in small amounts from dietary sources such as grains and meat. It is produced endogenously during the metabolism of choline to glycine. DMG has been widely used as a dietary supplement for purported benefits including improved physical performance and endurance; however clinical studies have shown little to no effect for these indications. Mechanistically, DMG may act at the glycine binding site of the NMDA receptor and has been proposed to enhance oxygen utilization by tissues and function as an antioxidant by serving as a source of glycine for glutathione synthesis. It also exhibits anti-inflammatory effects in cellular models. Despite its use in various conditions such as ADHD, epilepsy, chronic fatigue syndrome (CFS), allergies, respiratory disorders and multiple sclerosis among others—there is insufficient evidence supporting its efficacy for these uses[1][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N,N-dimethylglycine.